Morning Brief
Market Pulse: Stocks shrugged off a cooler-than-expected CPI print to nudge the S&P ahead, even as IBM’s warning sent legacy names reeling.
Key Movers: ASML tops Q2 estimates on strong AI chip demand, CrowdStrike Climbs 11%, Palo Alto Rises 7% as Cybersecurity Stocks Rally on Cooling Inflation, and Celcuity Announces FDA Approval of REVTORPYK™ stole the biotech spotlight.
Macro & Politics: A sudden geopolitical twist fueled a massive crypto short squeeze, liquidating over $275M in one wave and over $105M more an hour later.
What’s Next: Watch for CPI, PPI, and fresh Fed commentary later this week to spot the next market inflection.
Market Commentary
Everyone’s missing the biotech M&A drumbeat after Celcuity’s FDA OK for REVTORPYK™ (GlobeNewswire) and SS Innovations’ CFO hire (GlobeNewswire). While bulls cheer the next-gen treatment pipelines, the real move is the takeover chatter simmering behind the scenes—it’s a freakin’ big clue for sharp traders.
Look at ASML’s Q2 beat on AI chip demand (Crypto Briefing) and the $275M–plus crypto short squeeze ignited by geopolitical shifts (Crypto Briefing). They seem worlds apart, but both flows are underpinned by a damn global liquidity surge that’s blindsiding investors to Fed tightening risks.
Don’t just ride the wave—set strict exit points on crypto positions, lean into quality hardware names ahead of ASML’s guidance, and ready your portfolio for Fed speak this week. Play offense, but pack a helmet.
📈 Breaking Financial News
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
MINNEAPOLIS, July 14, 2026 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced that the U.S. Food and Drug Administration …
Crypto market rebounds, liquidates over $275M in short positions as geopolitical shift triggers massive short squeeze
The crypto market's rebound highlights the volatility and risk of geopolitical influences, emphasizing the need for cautious investment strategies.
A ‘Healthy' U.S. Economy Spurs Bank of America, Wells Fargo Earnings Beat
This may happen as a result of the following:
– Javascript is disabled or blocked by an extension (ad blockers for example)
– Your browser does not support cookies
Reference ID: #c90d012c-7f7f-11f1-b655-cacba96650bf
This may happen as a result of the followin…
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
ROCKVILLE, Md., July 14, 2026 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, celebrates the five-yea…
ASML tops Q2 estimates on strong AI chip demand
ASML's dominance in lithography tech underpins AI and crypto advancements, highlighting its pivotal role in future tech infrastructure and markets.
Something doesn't add up. Jobs that “existed”… didn't in reality.
The government deploying record AI spending. Yet Buffett holds $344B cash—his largest position EVER. Louis Navellier's grading system (46 years tracking money flows) reveals what the Wall Street elite see but won't tell you.
🔍 Market Analysis & Insights
LTTS shares up 4% as Q1 profit and revenue rise, Anthropic partnership
L&T Technology Services shares rise 4% after strong Q1 earnings and a partnership with Anthropic to enhance engineering processes.
GQG Partners just downgraded at Goldman Sachs, here's why
See the rest of the story here. TheFly provides the latest financial news as it breaks, known for real-time market intelligence for investors and traders.
CrowdStrike Climbs 11%, Palo Alto Rises 7% as Cybersecurity Stocks Rally on Cooling Inflation
Cooler inflation data sent cybersecurity stocks surging Tuesday, but the real question is whether today's spike reflects genuine conviction or a rate-cut sug…
B. Braun Announces Approval and Commercialization of First Generic Sugammadex Injection in the U.S. Market
BETHLEHEM, Pa., July 14, 2026 /PRNewswire/ — B. Braun Medical Inc. announced the U.S. Food and Drug Administration approval of Sugammadex Injection, 200 mg/2 mL…
S&P 500 rises after June CPI; IBM stock falls 22% on profit warning
June CPI came in at 3.5% annually, below the 3.8% economists expected, but rising oil prices and an IBM warning capped gains.
The Elon Musk “Mystery Metal” That Could Break China's Grip Trump called America's rare-ea
Quietly engineered by Elon Musk… could end that crisis forever. And one tiny company is sitting at the center of it all. Musk is expected to make an announcement any day now. See more about this secret project here.
💰 Investment Opportunities
Over $105M in short positions liquidated from crypto market in past hour
The rapid liquidation highlights the inherent risks of leveraged trading in volatile markets, emphasizing the need for cautious investment strategies.
GLP-1 Drugs Like Ozempic and Wegovy May Be Improving a Painful Skin Disease, Dermatologists Say
New evidence links GLP-1 drugs like Ozempic and Wegovy to significant improvements in psoriasis and hidradenitis suppurativa. Dermatologists explain what the data show and who may benefit.
SS Innovations Appoints Sarah M. Romano as Chief Financial Officer
Veteran medtech finance executive brings extensive public company and capital markets experience to support the Company's next phase of global growth.
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
– Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America –
JPMorgan beats profit expectations as equity-markets revenue surges
JPMorgan's profit surge highlights the potential for robust equity market performance to set new benchmarks for banking sector earnings.